Skip to menu Skip to content Skip to footer
Dr Richard Fernandes
Dr

Richard Fernandes

Email: 

Overview

Background

Richard Fernandes is an Inflammatory Bowel Disease specialist at Mater Hospital Brisbane and the Royal Brisbane and Women's Hospital. He is an active clinician researcher, including extensive involvement in numerous international clinical trials for IBD therapeutics. Supported by a scholarship from Crohn's and Colitis Australia, Richard is currently completing a PhD in post-operative Crohn's disease, including investigating the role of the mucosa-associated microbiome and mesentery in disease recurrence, and evaluating monitoring strategies post-operatively. His other interests include endoscopic management of IBD strictures and intestinal ultrasound.

Availability

Dr Richard Fernandes is:
Available for supervision
Media expert

Works

Search Professor Richard Fernandes’s works on UQ eSpace

44 works between 2020 and 2025

21 - 40 of 44 works

2023

Conference Publication

Cystic artery pseudoaneurysm treated with ultrasound-guided percutaneous collagen injection

Malloy, R., Fernandes, R., Van Tonder, F. and Haque, M. (2023). Cystic artery pseudoaneurysm treated with ultrasound-guided percutaneous collagen injection. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2 - 5 September 2023. Richmond, VIC Australia: John Wiley and Sons. doi: 10.1111/jgh.16291

Cystic artery pseudoaneurysm treated with ultrasound-guided percutaneous collagen injection

2023

Conference Publication

Cessation of corticosteroids after acute severe ulcerative colitis may be associated with increased colectomy risk: Results of the ANZ-ASUC study in collaboration with the ANZIBDC

Fernandes, R., Gilmore, R., Ruddick-Collins, L., Rice, K., Moore, G., Gazelakis, K., Vasudevan, A., Zhang, J., Wright, E., Schildkraut, T., Clark, N., Schultz, M., Brownson, A., Haifer, C., Bracken, L. M. L., Mahy, G., Swe, E., Judge, C., Ngoi, B., Lynch, K., Begun, J. and An, Y-K (2023). Cessation of corticosteroids after acute severe ulcerative colitis may be associated with increased colectomy risk: Results of the ANZ-ASUC study in collaboration with the ANZIBDC. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons.

Cessation of corticosteroids after acute severe ulcerative colitis may be associated with increased colectomy risk: Results of the ANZ-ASUC study in collaboration with the ANZIBDC

2023

Conference Publication

Impact of point-of-care intestinal ultrasound in patients with inflammatory bowel disease

Tan, W. L., Barr, E., Pham, H., Fernandes, R., Khoo, E., An, Y-K and Begun, J. (2023). Impact of point-of-care intestinal ultrasound in patients with inflammatory bowel disease. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2-5 September 2023. Richmond, VIC Australia: John Wiley & Sons.

Impact of point-of-care intestinal ultrasound in patients with inflammatory bowel disease

2023

Conference Publication

Durability of escalated anti-tumor necrosis factor (TNF) therapy in Crohn's disease is similar between TNF-naive and TNF-experienced patients and may be improved with proactive drug monitoring: An Australian multicenter experience

Gilmore, R., Fernandes, R., Schildkraut, T., Joshi, R., Lin, L., Etchegaray, A., Anandan, A. Shanmuga, Begun, J., An, Y-K and Wright, E. (2023). Durability of escalated anti-tumor necrosis factor (TNF) therapy in Crohn's disease is similar between TNF-naive and TNF-experienced patients and may be improved with proactive drug monitoring: An Australian multicenter experience. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2-5 September 2023. Richmond, VIC Australia: John Wiley & Sons.

Durability of escalated anti-tumor necrosis factor (TNF) therapy in Crohn's disease is similar between TNF-naive and TNF-experienced patients and may be improved with proactive drug monitoring: An Australian multicenter experience

2023

Journal Article

Upadacitinib salvage therapy for infliximab experienced patients with acute severe ulcerative colitis

Gilmore, Robert, Tan, Lian, Fernandes, Richard, An, Yoon-Kyo and Begun, Jakob (2023). Upadacitinib salvage therapy for infliximab experienced patients with acute severe ulcerative colitis. Journal of Crohn's and Colitis, 17 (12), 2033-2036. doi: 10.1093/ecco-jcc/jjad115

Upadacitinib salvage therapy for infliximab experienced patients with acute severe ulcerative colitis

2023

Conference Publication

Post-Ustekinumab induction IL-12, IL-13 and Ustekinumab levels are associated with clinical response in a multicentre prospective cohort study of Crohn's disease patients: results from the Aurora study

An, Yoon-Kyo, Lindsay, Niamh, Allan, Natalie, Khoo, Emi, Fernandes, Richard, Amiss, Anna, Pham, Hai, Wong, Kam Fai, Ooi, Soong-Yuan, Thin, Lena, Lightowler, Daniel, Connor, Susan J., Williams, Astrid-Jane, De Cruz, Peter, Suen, Christopher Li Wai, Kariyawasam, Viraj C., Mitrev, Nikola, Ghaly, Dr Simon, Andrews, Jane M., Christensen, Britt, Sparrow, Miles, White, Lauren S., Bryant, Robert V., Ding, Nik S., Leong, Rupert, Van Langenberg, Daniel R., Seltenreich, Hansjoerg, Subramaniam, Kavitha, Radford-Smith, Graham L. and Begun, Jakob (2023). Post-Ustekinumab induction IL-12, IL-13 and Ustekinumab levels are associated with clinical response in a multicentre prospective cohort study of Crohn's disease patients: results from the Aurora study. Digestive Disease Week DDW / AGA Conference 2023, Chicago, IL United States, 6-9 May 2023. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(23)03564-3

Post-Ustekinumab induction IL-12, IL-13 and Ustekinumab levels are associated with clinical response in a multicentre prospective cohort study of Crohn's disease patients: results from the Aurora study

2023

Conference Publication

Baseline cytokine levels and microbiome signatures are associted with clinical response following ustekinumab induction in a multi-centre prospective cohort study of crohn's disease patients: results from the aurora study

An, Yoon-Kyo, Lindsay, Niamh, Allan, Natalie, Khoo, Emi, Fernandes, Richard, Amiss, Anna, Pham, Hai, Giri, Rabina, Ooi, Soong-Yuan, Thin, Lena, Lightowler, Daniel, Connor, Susan J., Williams, Astrid-Jane, De Cruz, Peter, Suen, Christopher Li Wai, Kariyawasam, Viraj C., Mitrev, Nikola, Ghaly, Simon, Andrews, Jane M., Christensen, Britt, Sparrow, Miles, White, Lauren S., Bryant, Robert V., Ding, Nik S., Leong, Rupert, Van Langenberg, Daniel R., Seltenreich, Hansjoerg, Subramaniam, Kavitha, Radford-Smith, Graham L. and Begun, Jakob (2023). Baseline cytokine levels and microbiome signatures are associted with clinical response following ustekinumab induction in a multi-centre prospective cohort study of crohn's disease patients: results from the aurora study. Digestive Disease Week (DDW), Chicago, IL United States, 6-9 May 2023. Philadelphia, PA United States: Elsevier. doi: 10.1016/S0016-5085(23)02531-3

Baseline cytokine levels and microbiome signatures are associted with clinical response following ustekinumab induction in a multi-centre prospective cohort study of crohn's disease patients: results from the aurora study

2023

Conference Publication

Reduction of bowel wall thickness and doppler signals as eary as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of acute severe ulcerative colitis: USUC study including genius cohort

An, Yoon-Kyo, Fernandes, Richard, Lindsay, Niamh, Khoo, Emi, Pham, Hai, Wong, Kam Fai, Thin, Lena, Goodsall, Thomas, Bryant, Robert V., Wright, Emily K., Smith, Rebecca, Friedman, Antony and Begun, Jakob (2023). Reduction of bowel wall thickness and doppler signals as eary as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of acute severe ulcerative colitis: USUC study including genius cohort. Digestive Disease Week (DDW) 2023, Chicago, IL United States, 6-9 May 2023. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(23)03032-9

Reduction of bowel wall thickness and doppler signals as eary as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of acute severe ulcerative colitis: USUC study including genius cohort

2023

Conference Publication

Reduction of bowel wall thickness and doppler signals as eary as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of acute severe ulcerative colitis: USUC study including genius cohort

An, Yoon-Kyo, Fernandes, Richard, Lindsay, Niamh, Khoo, Emi, Pham, Hai, Wong, Kam Fai, Thin, Lena, Goodsall, Thomas, Bryant, Robert V., Wright, Emily K., Smith, Rebecca, Friedman, Antony and Begun, Jakob (2023). Reduction of bowel wall thickness and doppler signals as eary as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of acute severe ulcerative colitis: USUC study including genius cohort. Digestive Disease Week (DDW), Chicago, IL United States, 6-9 May 2023. Philadelphia, PA United States: Elsevier.

Reduction of bowel wall thickness and doppler signals as eary as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of acute severe ulcerative colitis: USUC study including genius cohort

2023

Conference Publication

Post-ustekinumab induction IL-12, IL-23, and ustekinumab levels are associated with clinical response in a multicentre prospective cohort study of Crohn's disease patients: results from the Aurora Study

An, Yoon-Kyo, Lindsay, Niamh, Allan, Natalie, Khoo, Emi, Fernandes, Richard, Amiss, Anna, Pham, Hai, Wong, Kam Fai, Ooi, Soong-Yuan, Thin, Lena, Lightowler, Daniel, Connor, Susan J., Williams, Astrid-Jane, De Cruz, Peter, Suen, Christopher Li Wai, Kariyawasam, Viraj C., Mitrev, Nikola, Ghaly, Simon, Andrews, Jane M., Christensen, Britt, Sparrow, Miles, White, Lauren S., Bryant, Robert V., Ding, Nik S., Leong, Rupert, Van Langenberg, Daniel R., Seltenreich, Hansjoerg, Subramaniam, Kavitha, Radford-Smith, Graham L. and Begun, Jakob (2023). Post-ustekinumab induction IL-12, IL-23, and ustekinumab levels are associated with clinical response in a multicentre prospective cohort study of Crohn's disease patients: results from the Aurora Study. Digestive Disease Week (DDW), Chicago, IL United States, 6-9 May 2023. Philadelphia, PA United States: Elsevier.

Post-ustekinumab induction IL-12, IL-23, and ustekinumab levels are associated with clinical response in a multicentre prospective cohort study of Crohn's disease patients: results from the Aurora Study

2023

Conference Publication

Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn's disease patients: results from the AURORA Study including ANZIBDC Cohort

An, Y. K., Lindsay, N., Allan, N., Khoo, E., Fernandes, R., Amiss, A., Pham, H., Wong, K. F., Ooi, S. Y., Thin, L., Lightowler, D., Connor, S. J., Williams, A. J., De Cruz, P., Suen, C. Li Wai, Kariyawasam, V., Mitrev, N., Ghaly, S., Andrews, J. M., Christensen, B., Sparrow, M. P., White, L. S., Bryant, R. V., Ding, N., Leong, R., Van Langenberg, D., Seltenreich, H., Subramaniam, K., Radford-Smith, G. and Begun, J. (2023). Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn's disease patients: results from the AURORA Study including ANZIBDC Cohort. 18th Congress of ECCO, Copenhagen, Denmark, 1-4 March 2023. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjac190.0793

Post-ustekinumab induction IL12, IL23, and ustekinumab levels are associated with clinical response in a multi-centre prospective cohort study of Crohn's disease patients: results from the AURORA Study including ANZIBDC Cohort

2023

Conference Publication

Reduction of bowel wall thickness and doppler signals as early as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of Acute Severe Ulcerative Colitis: USUC Study including the GENIUS cohort

An, Y. K., Fernandes, R., Lindsay, N., Khoo, E., Pham, H., Wong, K. F., Thin, L., Goodsall, T., Bryant, R. V., Wright, E., Smith, R., Friedman, A., Begun, J. and Gastroenterology Network of Intestinal Ultrasound (GENIUS) (2023). Reduction of bowel wall thickness and doppler signals as early as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of Acute Severe Ulcerative Colitis: USUC Study including the GENIUS cohort. 18th Congress of ECCO, Copenhagen, Denmark, 1-4 March 2023. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjac190.0744

Reduction of bowel wall thickness and doppler signals as early as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of Acute Severe Ulcerative Colitis: USUC Study including the GENIUS cohort

2022

Conference Publication

Post-induction IL-12/23 levels correlate with clinical response and remission after ustekinumab in a multicenter prospective cohort study of patients with Crohn’s disease: Preliminary induction results of the AURORA study, including the Australia New Zealand IBD Consortium Cohort

An,Yoon-Kyo, Lindsay, Niamh, Allan, Natalie, Khoo, Emi, Amiss, Anna, Moniruzzaman, Md, Fernandes, Richard, Ooi, Soong-Yuan J., Thin, Lena W.Y., Mstj, Daniel Lightowler, Connor, Susan, Williams, Astrid-Jane, De Cruz, Peter, Suen, Christopher Li Wai, Kariyawasam, Viraj C., Mitrev, Nicola, Ghaly, Simon, Andrews, Jane M., Christensen, Britt, Sparrow, Miles, White, Lauren, Bryant, Robert, Ding, Nik S., Leong, Rupert W., Van Langenberg, Daniel R., Seltenreich, Hans, Subramaniam, Kavitha, Radford-Smith, Graham and Begun, Jakob (2022). Post-induction IL-12/23 levels correlate with clinical response and remission after ustekinumab in a multicenter prospective cohort study of patients with Crohn’s disease: Preliminary induction results of the AURORA study, including the Australia New Zealand IBD Consortium Cohort. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2022, Sydney, NSW Australia, 9–11 September 2022. Richmond, VIC Australia: John Wiley & Sons. doi: 10.1111/jgh.15953

Post-induction IL-12/23 levels correlate with clinical response and remission after ustekinumab in a multicenter prospective cohort study of patients with Crohn’s disease: Preliminary induction results of the AURORA study, including the Australia New Zealand IBD Consortium Cohort

2022

Conference Publication

Biologic-experienced ulcerative colitis: a distinct disease phenotype

Fernandes, R., Llewelyn, J., Radford-Smith, G. and Croft, A. (2022). Biologic-experienced ulcerative colitis: a distinct disease phenotype. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2022, Sydney, NSW, Australia, 9 - 11 September 2022. Richmond, VIC, Australia: John Wiley & Sons. doi: 10.1111/jgh.15953

Biologic-experienced ulcerative colitis: a distinct disease phenotype

2022

Conference Publication

Ocrelizumab-induced medically refractory fulminant colitis requiring colectomy

Malloy, R., Fernandes, R., Begun, J. and An, Y-K (2022). Ocrelizumab-induced medically refractory fulminant colitis requiring colectomy. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2022, International Convention Centre Sydney (ICC Sydney), Sydney, NSW, Australia, 9 - 11 September 2022. Richmond, VIC, Australia: John Wiley & Sons. doi: 10.1111/jgh.15953

Ocrelizumab-induced medically refractory fulminant colitis requiring colectomy

2022

Journal Article

Editorial: is older-onset ulcerative colitis more severe or less aggressively managed?

Fernandes, Richard G. and Radford-Smith, Graham (2022). Editorial: is older-onset ulcerative colitis more severe or less aggressively managed?. Alimentary Pharmacology & Therapeutics, 55 (10), 1350-1351. doi: 10.1111/apt.16905

Editorial: is older-onset ulcerative colitis more severe or less aggressively managed?

2020

Conference Publication

The application of Baveno VI criteria to improve value care and reduce risk exposure for patients with chronic liver disease

Vaux, L., Fernandes, R., Bradbear, J., Pakneshan, S., Thompson, H., Hewawasam, S., Hodgson, R., Pan, A., Kasi, M. and Rahman, T. (2020). The application of Baveno VI criteria to improve value care and reduce risk exposure for patients with chronic liver disease. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2020, Virtual, 21 - 30 November 2020. Richmond, VIC, Australia: John Wiley & Sons. doi: 10.1111/jgh.15269

The application of Baveno VI criteria to improve value care and reduce risk exposure for patients with chronic liver disease

2020

Conference Publication

Audit of response to conservative management in acute food boluses

Connolly, E., Bradbear, J., Fernandes, R., Pakneshan, S., Hewawasam, S., Vaux, L., Kasi, M., Hodgson, R., Pan, A. and Rahman, T. (2020). Audit of response to conservative management in acute food boluses. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2020, Virtual, 21 - 30 November 2020. Richmond, VIC, Australia: John Wiley & Sons. doi: 10.1111/jgh.15277

Audit of response to conservative management in acute food boluses

2020

Conference Publication

A visual tool for hepatic osteodystrophy screening in patients with chronic liver disease

De'Ambrosis, S., Bradbear, J., Thompson, H., Fernandes, R., Pakneshan, S., Vaux, L., Hewawasam, S., Kasi, M., Pan, A., Hodgson, R. and Rahman, T. (2020). A visual tool for hepatic osteodystrophy screening in patients with chronic liver disease. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2020, Virtual, 21 - 30 November 2020. Richmond, VIC, Australia: John Wiley & Sons. doi: 10.1111/jgh.15269

A visual tool for hepatic osteodystrophy screening in patients with chronic liver disease

2020

Conference Publication

Colonoscopy surveillance workload before and after implementation of new National Health and Medical Research Council guidelines

Pakneshan, S., Bradbear, J., Vaux, L., Fernandes, R., Hewawasam, S., Hodgson, R., Kasi, M., Pan, A., Vandeleur, A., Wright, E., Harch, J. and Rahman, T. (2020). Colonoscopy surveillance workload before and after implementation of new National Health and Medical Research Council guidelines. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2020, Virtual, 21 - 30 November 2020. Richmond, VIC, Australia: John Wiley & Sons. doi: 10.1111/jgh.15277

Colonoscopy surveillance workload before and after implementation of new National Health and Medical Research Council guidelines

Supervision

Availability

Dr Richard Fernandes is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Media

Enquiries

Contact Dr Richard Fernandes directly for media enquiries about their areas of expertise.

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au